Head-to-head · Cost-Efficiency Index
Meto vs Risen Labs
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Meto
Cost-first shoppers who want peptide/longevity enthusiasts who want lab-verified dosing across multiple protocols, not GLP-1-first shoppers.
Visit MetoRisen Labs
Patients in New York or Colorado also interested in hormone/men's health programs.
Visit Risen LabsThe verdict
Meto and Risen Labs tie on the Cost-Efficiency Index at 44/100, so neither wins outright on the numbers. For most shoppers we'd start with Meto (ranked #480, a hair above #485) — Cost-first shoppers who want peptide/longevity enthusiasts who want lab-verified dosing across multiple protocols, not GLP-1-first shoppers. But Risen Labs is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Meto.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Meto | Risen Labs |
|---|---|---|
| Cost-Efficiency Index | 44/100 | 44/100 |
| Semaglutide / mo | $199/mo (starting dose, plus a separate fee, compounded) | Not disclosed |
| Tirzepatide / mo | $199/mo (starting dose, plus a separate fee, compounded) | Not disclosed |
| Semaglutide / yr (modeled) | $2,388 | — |
| Tirzepatide / yr (modeled) | $2,388 | — |
| Coverage | Coverage not published | 2 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #480 | #485 |
Meto
44/100Where the value is
- Requires actual bloodwork/metabolic panel before prescribing, a stronger clinical gate than many peers
- Transparent line-item pricing across a wide menu of protocols
- Combined GLP-1 pricing is comparatively affordable relative to single-drug peers
The tradeoffs
- GLP-1 is a minor line item on a broader peptide platform, not the core focus
- Semaglutide and tirzepatide are not priced or dosed separately -- shoppers can't compare against single-drug competitors cleanly
Risen Labs
44/100Where the value is
- LegitScript certified
- Requires a live synchronous video consult, not just an async form
- Uses a 503A compounding pharmacy per its own disclosure
The tradeoffs
- Licensed in only 2 states (New York, Colorado) versus the near-nationwide reach of most competitors
- No pricing disclosed anywhere on the public site
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.